Lisa A. Hayes
No más puestos en curso
Perfil
Lisa A.
Hayes worked as Senior Director of Investor Relations at Celgene Corp.
and as Head of Investor Relations & Corporate Communications at ProQR Therapeutics NV and Tmunity Therapeutics, Inc. She also worked as VP of Investor Relations & Corporate Communications at Cyteir Therapeutics, Inc. from 2021 to 2023.
Ms. Hayes holds a graduate degree from New York University, a Master's in Business Administration from St. Joseph's University, and an undergraduate degree from Seton Hall University.
Antiguos cargos conocidos de Lisa A. Hayes.
| Empresas | Cargo | Fin |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Contacto de Relaciones con Inversores | 01/02/2023 |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Contacto de Relaciones con Inversores | - |
| PROQR THERAPEUTICS N.V. | Contacto de Relaciones con Inversores | - |
| CELGENE | Public Communications Contact | - |
Formación de Lisa A. Hayes.
| St. Joseph's University | Masters Business Admin |
| New York University | Graduate Degree |
| Seton Hall University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| PROQR THERAPEUTICS N.V. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
- Bolsa de valores
- Insiders
- Lisa A. Hayes
